<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The <z:mpath ids='MPATH_271'>adenomatous polyposis coli</z:mpath> (APC) locus on chromosome 5q21-22 shows frequent loss of heterozygosity (LOH) in <z:hpo ids='HP_0011459'>esophageal carcinomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the prevalence of truncating mutations in the APC gene in <z:hpo ids='HP_0011459'>esophageal carcinomas</z:hpo> is low </plain></SENT>
<SENT sid="2" pm="."><plain>Because hypermethylation of promoter regions is known to affect several other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes, we investigated whether the APC promoter region is hypermethylated in <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> patients and whether this abnormality could serve as a prognostic plasma biomarker </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We assayed DNA from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue and matched plasma from <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> patients for hypermethylation of the promoter region of the APC gene </plain></SENT>
<SENT sid="4" pm="."><plain>We used the maximal chi-square statistic to identify a discriminatory cutoff value for hypermethylated APC DNA levels in plasma and used bootstrap-like simulations to determine the P: value to test for the strength of this association </plain></SENT>
<SENT sid="5" pm="."><plain>This cutoff value was used to generate Kaplan-Meier survival curves </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> P values were based on two-sided tests </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Hypermethylation of the promoter region of the APC gene occurred in abnormal esophageal tissue in 48 (92%) of 52 patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, in 16 (50%) of 32 patients with esophageal <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo>, and in 17 (39.5%) of 43 patients with Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> but not in matching <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal tissues </plain></SENT>
<SENT sid="8" pm="."><plain>Hypermethylated APC DNA was observed in the plasma of 13 (25%) of 52 <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> patients and in two (6.3%) of 32 squamous <z:mp ids='MP_0002038'>carcinoma</z:mp> patients </plain></SENT>
<SENT sid="9" pm="."><plain>High plasma levels of methylated APC DNA were statistically significantly associated with reduced patient survival (P =.016) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The APC promoter region was hypermethylated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of the majority of patients with primary esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>Levels of hypermethylated APC gene DNA in the plasma may be a useful biomarker of biologically <z:e sem="disease" ids="C0001807" disease_type="Mental or Behavioral Dysfunction" abbrv="">aggressive disease</z:e> in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> patients and should be evaluated as a potential biomarker in additional <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types </plain></SENT>
</text></document>